Structure Therapeutics (GPCR) Return on Capital Employed (2023 - 2026)
Structure Therapeutics (GPCR) posted quarterly Return on Capital Employed of 14.08% for Q1 2026, up 743.0% year-over-year from 1.67% in Q1 2025, and up 8.72% quarter-over-quarter from 15.42% in Q4 2025.
Structure Therapeutics (GPCR) Return on Capital Employed (2023 - 2026) Analysis & Trends
Structure Therapeutics' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 14.08% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 743.0% year-over-year to 14.08%; the TTM figure through Mar 2026 stood at 14.08% (up 743.0% YoY), while the FY2025 annual figure was 14.96%, up 914.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 14.08%, up from 15.42% in the prior quarter.
- The five-year high for Return on Capital Employed was 14.08% in Q1 2026, with the low at 41.78% in Q3 2023.
- The 4-year median for Return on Capital Employed is 25.81% (2024), against an average of 25.4%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 2610 bps in 2024, then plunged 1661 bps in 2025.
- Structure Therapeutics' Return on Capital Employed stood at 31.68% in 2023, then soared by 43 bps to 17.93% in 2024, then advanced by 14 bps to 15.42% in 2025, then gained by 9 bps to 14.08% in 2026.
- Business Quant data shows GPCR's Return on Capital Employed at 14.08% in Q1 2026, 15.42% in Q4 2025, and 32.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -18.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.41% |
| Mar 31, 2026 | -14.08% |
| Dec 31, 2025 | -15.42% |
| Sep 30, 2025 | -32.29% |
| Jun 30, 2025 | -27.37% |
| Mar 31, 2025 | -21.51% |
| Dec 31, 2024 | -17.93% |
| Sep 30, 2024 | -15.68% |
| Jun 30, 2024 | -18.02% |
| Mar 31, 2024 | -25.81% |
| Dec 31, 2023 | -31.68% |
| Sep 30, 2023 | -41.78% |
| Jun 30, 2023 | -31.91% |
| Mar 31, 2023 | -36.67% |